Knudsen Files SC 13D for ImmuCell Corp

TL;DR

**Knudsen files 13D on IMMU, signaling stake change.**

AI Summary

Ejnar A. Knudsen III filed a Schedule 13D on August 27, 2024, reporting beneficial ownership of ImmuCell Corporation. The filing indicates a change in reporting status, potentially due to exceeding ownership thresholds or a change in investment intent. The specific date of the event requiring this filing was August 21, 2024.

Why It Matters

This filing signals a significant change in beneficial ownership for ImmuCell Corporation, potentially indicating increased investor interest or a shift in control dynamics.

Risk Assessment

Risk Level: medium — A Schedule 13D filing often indicates a significant stake or potential activist interest, which can introduce volatility and uncertainty for the company and its shareholders.

Key Players & Entities

• ImmuCell Corporation (company) — Subject Company
• Ejnar A. Knudsen III (person) — Filing Person
• August 27, 2024 (date) — Filing Date
• August 21, 2024 (date) — Event Date

FAQ

Key Financial Figures

• $0.10 — relates to the common stock, par value $0.10 per share, of ImmuCell Corporation, a D

Filing Documents

• d858394dsc13d.htm (SC 13D) — 33KB
• 0001193125-24-207799.txt ( ) — 34KB

From the Filing

SC 13D 1 d858394dsc13d.htm SC 13D SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.)* ImmuCell Corporation (Name of Issuer) Common Stock, par value $.10 per share (Title of Class of Securities) 45252306 (CUSIP Number) Ejnar A. Knudsen III 212 West Superior, Suite 500 Chicago, IL 60654 (530) 564-0626 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 21, 2024 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 45252306 1 Names of Reporting Persons I.R.S. Identification Nos. of above persons (entities only). Ejnar A. Knudsen III 2 Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3 SEC Use Only 4 Source of Funds (See Instructions) PF 5 Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6 Citizenship or Place of Organization USA Number of Shares Beneficially Owned By Each Reporting Person With: 7 Sole Voting Power 463,619 8 Shared Voting Power 0 9 Sole Dispositive Power 463,619 10 Shared Dispositive Power None 11 Aggregate Amount Beneficially Owned by Each Reporting Person 463,619 12 Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13 Percent of Class Represented by Amount in Row (11) 5.9% 1 14 Type of Reporting Person (See Instructions) IN 1 Based on the outstanding number of shares reported as being outstanding as of August 2, 2024 in ImmuCell Corporations Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024. Item1. Security and Issuer This Statement relates to the common stock, par value $0.10 per share, of ImmuCell Corporation, a Delaware corporation (the Company). The Companys principal executive offices are located at 56 Evergreen Drive, Portland, Maine 04103. Item2. Identity and Background. (a) Name . The name of the Reporting Person is Ejnar A. Knudsen III. (b) IL 60654. (c) Occupation and Employment . The Reporting Person is the founder and chief executive officer of AGR Partners. (d) Criminal Proceedings . During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) Civil Proceedings . During the last five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which the Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Citizenship . The Reporting Person is a citizen of the United States. Item3. Source and Amount of Funds or Other Consideration On August 21, 2024, the Reporting Person acquired beneficial ownership of 300,000 shares of Companys common stock which, when combined with earlier purchases, resulted in the Reporting Person holding more than 5.0% of the Companys outstanding common stock. The purchases were made using general investment funds. Item4. Purpose of Transaction All shares held by the Reporting Person are held by the Reporting Person for investment purposes. The Reporting Person currently has no plans or proposals that relate to, or would result in, any of the matters described in subsections (a) through (j) of Item 4 of the instructions to Schedule 13D. Item5. Interest in Securities of the Issuer As of the date hereof, the Reporting Person is the beneficial owner of 463,619 shares of common stock representing approximately 5.9% of the approximately 7,833,080 shares outstanding, as disclosed in the Companys Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 13, 2024. The Reporting Persons ownership consists of 386,425 owned by the Reporting Person directly, 9,539 shares owned by the Reporting

View Full Filing

View this SC 13D filing on SEC EDGAR